Who is sponsoring NCT04167943?

NCT04167943 is sponsored by Ain Shams University.

What drugs are being tested in NCT04167943?

Interventions in NCT04167943: Dual cured resin modified tricalcium silicate cement.

What condition does NCT04167943 study?

NCT04167943 studies Reversible Pulpitis.

Is NCT04167943 still recruiting?

NCT04167943 is currently completed. Last updated 14 June 2022.

Last reviewed 2022-06-14 · How we verify

NCT04167943

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conservative Pulp Therapy of Primary Molars Using TheraCAL

Completed Phase 3 Last updated 14 June 2022

What this trial tests

Phase 3 trial testing Dual cured resin modified tricalcium silicate cement in Reversible Pulpitis in 216 participants. Completed in 1 September 2021.

Timeline

25 November 2019

Primary endpoint
1 August 2021

1 September 2021

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	216
Start date	25 November 2019
Primary completion	1 August 2021
Estimated completion	1 September 2021
Sites	1 location across Egypt

Drugs / interventions tested

Dual cured resin modified tricalcium silicate cement — full drug profile →

Conditions studied

Reversible Pulpitis — all drugs for Reversible Pulpitis →

Sponsor

Ain Shams University

Who can join

Adults 4 to 6, any sex, with Reversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a clinical trial that assesses the clinical and radiographic success rates of 3 conservative pulp therapy treatments in primary molars compared to conventional pulpotomy using a bioactive dual cured calcium silicate cement (TheraCAL PT).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of four vital pulp therapies for primary molars using a dual-cured tricalcium silicate (TheraCal PT): one-year results of a non-randomized clinical trial.
Wassel M, Hamdy D, Elghazawy R. · · 2023 · cited 6× · PMID 36890738 · DOI 10.22514/jocpd.2023.004

Verify or expand the search:

Other recruiting trials for Reversible Pulpitis

Currently open trials in the same condition.

NCT07073573 — Evaluation of Pulpal Biomarkers in Vital Pulp Therapy · NA · active not recruiting
NCT07391124 — In Vivo Pulp Thermal Changes During Different Slenderization Techniques · NA · active not recruiting
NCT06844448 — The Effect of Different Risk Factors on the Success Rate of VPT · recruiting
NCT06433297 — Comparative Evaluation of Indirect vs. Direct Pulp Capping in Deep Carious Mandibular Molars · NA · recruiting
NCT07101068 — Assessment of Pain and Anxiety During Infiltration Anesthesia Using Dental Anesthesia Injector Versus Conventional Syrin · NA · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04167943 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 14 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04167943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing